Richard R.P. Warner, MD
Professor of Medicine
Mount Sinai School of Medicine
5 East 98th Street, 11th Floor
New York, NY 10029
Telephone: 212-241-4299
Fax: 212-426-5099
Richard R.P. Warner, MD is Professor of Medicine and Director of the Carcinoid NeuroEndocrine Tumor Center at Mount Sinai School of Medicine, and Medical Director of the Carcinoid Cancer Foundation, Inc.
Dr. Warner earned his BA at Oberlin College and his MD at the University of Cincinnati (1951). He completed internal medicine residency and gastroenterology fellowships at Mount Sinai Hospital and Bronx VA Hospital and then served as a Research Fellow and Research Assistant and NIH trainee at Mount Sinai.
In 1972, Dr. Warner was awarded the honor of Grand Commander of the Humane Order of African Redemption (Monrovia), and won the 2002 Catherine Margaret Pasmantier Award of the New York Cancer Society and the Fund for Blood and Cancer Research. In October 2009 he was honored to be the first recipient of the annual Lifetime Achievement Award of The North American NeuroEndocrine Tumor Society (NANETS) for a lifetime of work and accomplishment with carcinoid/NETS.
In addition to his current academic positions, he is the Principal Investigator of the longest continuously IRB-approved research project at Mount Sinai School of Medicine (since 1958) and he is an advisor to the Board of Directors of NANETS of which he was a founding member.
Dr. Warner is author or co-author of scores of publications on carcinoid and related NETs in peer-reviewed journals, in addition to abstracts and chapters in textbooks, as well as numerous lectures, presentations, and poster exhibits. Perhaps most notable are: the first description of carcinoid syndrome resulting from bronchial carcinoid (1958); hyperserotoninemia in IBS (1963); the first report of intrahepatic artery injection of Y-90 microspheres for treatment of carcinoid liver metastases-5 cases- (1968), the first large series reported of carcinoid syndrome patients treated by hepatic artery chemoembolus injection (HACE) (1985); and the first description of pharmacologic management of a large series (80 patients) with carcinoid metastases to the liver treated by HACE (2001). In June 2008 he coauthored a multi-institutional report on the outcome of Yttrium-90 radioembolus treatment of NeuroEndocrine tumor metastases of the liver in 148 cases.
He continues actively involved in teaching, clinical practice, and research.
click to return to Ottawa 2012 List of Speakers | Vancouver 2010 List | 2008 Speakers